ViiV Healthcare announces positive result in TANGO Phase 3 study
Category: #health  By Pankaj Singh  Date: 2019-07-11
  • share
  • Twitter
  • Facebook
  • LinkedIn

ViiV Healthcare announces positive result in TANGO Phase 3 study

ViiV Healthcare Limited, a pharmaceutical company specializing in HIV treatment, recently announced positive results from Phase 3 TANGO study.

The study was conducted to assess viral suppression in adults with HIV1 with a 2 drug regimen of dolutegravir in combination with lamivudine. Patients were chosen on the basis that they had previously maintained viral suppression for at least 6 months on a TAF (Tenofovir Alafenamide Fumarate) containing 3 drug regimens. It aimed to verify whether the same could be achieved through the 2 drug regimen. The results from the study will be presented at the 10th IAS Conference on HIV Science, in Mexico City.

Based on a proportion of participants with plasma HIV 1 RNA≥50 copies c/ml, using the Food & Drug Administration Snapshot algorithm at 48th week, the study has reportedly reached its primary end-point for non-inferiority. None of the patients developed treatment resistance in the dolutegravir and lamivudine arm of the study nor did they meet confirmed virologic withdrawal criteria. The safety results for the 2 drug regimen of dolutegravir in combination with lamivudine were consistent with the product labelling for the medicines.

Kimberly Smith, MD and Head of Global Research & Medical Strategy at ViiV Healthcare Limited, was reportedly quoted saying that the company has been developing the TANGO study to reduce the number of medicines in HIV treatment regimen to maintain viral suppression. The 48th week data from the final study proves that patients, who are already on treatment can maintain viral suppression if they switch from a 3 drug tenofovir alafenamide fumarate -containing regimen to a 2 drug regimen of dolutegravir in combination with lamivudine.

As per credible sources, the single-pill, 2-drug dolutegravir in combination with lamivudine, was authorized in U.S. earlier this year for the treatment of HIV-1 infection in adults with no ARV (antiretroviral) treatment history & with no known resistance to either lamivudine or dolutegravir. It was also authorized in Europe recently for the treatment of HIV 1 infection in adults & adolescents above 12 years, with minimum weight of 40 kg, with no known or suspected resistance to the INI (integrase inhibitor) class, or lamivudine.

Source credit: https://www.viivhealthcare.com/en-gb/media/press-releases/2019/july/viiv-healthcare-announces-phase-iii-study-meets-primary-endpoint/



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

Anova Enterprises expands AnovaOS™ to boost clinical development
Anova Enterprises expands AnovaOS™ to boost clinical development
By Pankaj Singh

The U.S-based Anova Enterprises, Inc. (Anova) has reportedly expanded the AnovaOS™ technology platform in order to boost the development of promising novel treatments. The platform brings pharmaceutical companies...

Serum Institute to Resume Oxford COVID-19 Vaccine’s Trail in India
Serum Institute to Resume Oxford COVID-19 Vaccine’s Trail in India
By Pankaj Singh

India’s Drugs Controller General (DCGI) has approved Pune-based Serum Institute of India (SII) to restart the clinical trial of the Oxford/AstraZeneca COVID-19 vaccine in India.

Everest Medicines Announces Cefepime-Taniborbactam Phase 1 Results

Everest Medicines Announces Cefepime-Taniborbactam Phase 1 Results
By Pankaj Singh

Everest Medicines announced the top-line results from the Phase 1 clinical trial of Taniborbactam with cefepime for treating infections caused by multi-drug resistant pathogens in China. Everest Medicines is a biopharm...